Eli Lilly and Company
Health Care · Pharmaceuticals
Structural read: incretin franchise (tirzepatide) is the single largest near-term revenue driver in pharma, with GLP-1 TAM estimates in the $100-150B range by early 2030s and LLY + $NVO splitting the duopoly. Capacity - not demand - has been the binding constraint; LLY has committed $50B+ cumulative capex across Indiana, North Carolina, and Europe to expand fill-finish and API.
Pipeline optionality from oral GLP-1 (orforglipron) and next-gen multi-agonists (retatrutide) extends the runway past tirzepatide LOE.
- Mounjaro + Zepbound combined run-rate scaling toward $30B+ as supply unlocks
- Orforglipron oral GLP-1 phase-3 readouts position LLY for the at-home segment $NVO cannot service with injectables
- Donanemab adds an Alzheimer's leg (Kisunla approved 2024) with no direct $BIIB-class competitor at scale
- $50B+ capex build is a moat: incretin manufacturing is the bottleneck, and CDMO partners ($CTLT, $TMO bioprocess) inherit spillover demand
- Compounded GLP-1 grey market and payer pushback on coverage compress realized price
- Pipeline single-point-of-failure: a tirzepatide safety signal or retatrutide failure resets the multiple
- ~30x forward P/E prices in flawless execution; any capacity slip or Medicare negotiation surprise asymmetric
- LOE clock on tirzepatide starts mid-2030s - pipeline must deliver to avoid a patent cliff
No key levels recorded for this ticker.